AI Article Synopsis
- Systemic symptoms associated with breast implants (SSBI) refer to various health issues that patients link to their breast implants, with many reporting symptom relief after removal.
- A study aimed to assess symptom improvement in patients who had their implants removed without removing any capsule, comparing those with SSBI to a control group without symptoms.
- Results showed that patients in the SSBI group experienced a significant reduction in symptoms (74%) within six months, indicating that implant removal alone can lead to relief similar to removal with capsule surgery.
Article Abstract
Background: Systemic symptoms associated with breast implants (SSBI) is a term used to describe a group of patients who attribute a variety of symptoms to their implants. Previous studies have shown symptom improvement after implant removal in these patients irrespective of whether part or all the implant capsule has been removed.
Objectives: The aim of this study was to evaluate implant removal with no capsule removed in symptomatic and control subjects.
Methods: Eligible study subjects were sequentially enrolled at 5 investigator sites. The SSBI Cohort included patients with systemic symptoms they attributed to their implants who requested explantation. The Non-SSBI Cohort included subjects without systemic symptoms attributed to their implants who requested explantation with or without replacement. All subjects agreed to undergo explantation without removal of any capsule.
Results: Systemic symptom improvement was noted in SSBI subjects without removal of the implant capsule, comparable to the results of our previously published study. SSBI patients showed a 74% reduction in self-reported symptoms at 6 months with no capsulectomy which was not statistically different from partial or total capsulectomies (P = .23).
Conclusions: Explantation with or without capsulectomy provides symptom improvement in patients with systemic symptoms they associate with their implants.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/asj/sjae034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Approach to Scabies in Children: An Update].
Acta Med Port
January 2025
Serviço de Dermatologia. Unidade Local de Saúde Santo António. Porto. Portugal.
Scabies is a common dermatological infection that globally affects more than 200 million people. It is caused by the parasite Sarcoptes scabiei var. hominis and its transmission primarily occurs through direct contact.
View Article and Find Full Text PDF[How did men report their long COVID experience? Health-Disease socio-anthropological meaning].
Cien Saude Colet
January 2025
Escola de Enfermagem, Universidade Federal da Bahia. Salvador BA Brasil.
The study aims to explain the discourse of the collective subject of adult and elderly men about the experience of long COVID. Qualitative research, derived from a national multicenter clinical-virtual observatory involving 92 adult men, between 2022 and 2023 in Brazil. IRaMuTeQ software was used (data processing), the Collective Subject Discourse technique (analysis) and socio-anthropological references of the disease experience (interpretation).
View Article and Find Full Text PDFScrub typhus association with autoimmune biomarkers and clinical implications.
PLoS Negl Trop Dis
January 2025
Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Background: Scrub typhus, a disease caused by Orientia tsutsugamushi, triggers systemic vasculitis and is prevalent in Eastern and Southern Asia. This study aimed to uncover the relationship between scrub typhus and autoimmune responses, focusing on antinuclear antibodies (ANAs) and the implications of elevated ANA titers during infection.
Method: Data from a total of 139 patients diagnosed with scrub typhus and 30 healthy controls were retrospectively analyzed through serum samples to assess the levels of ANAs and related autoantibodies.
A comparative analysis of risk stratification tools in systemic sclerosis-associated pulmonary arterial hypertension: a EUSTAR analysis.
Rheumatology (Oxford)
January 2025
Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Objectives: The 2022 European Society of Cardiology and European Respiratory Society (ESC/ERS) Guidelines for pulmonary arterial hypertension (PAH) recommend risk stratification to optimize management. However, the performance of generic PAH risk stratification tools in patients with systemic sclerosis (SSc)-associated PAH remains unclear. Our objective was to identify the most accurate approach for risk stratification at SSc-PAH diagnosis.
View Article and Find Full Text PDFFoot peripheral sensory neuropathy: a frequent disabling manifestation in systemic sclerosis.
Rheumatology (Oxford)
January 2025
Leeds Institute of Rheumatic and Musculoskeletal Medicine, School of Medicine, University of Leeds, Leeds, UK.
Objectives: Peripheral Sensory Neuropathy (PSN) is an under-recognized feature in systemic sclerosis (SSc). Moreover, SSc foot involvement is frequent but poorly investigated. We aimed to provide a detailed characterization of foot PSN in a large cohort of SSc patients, describing its associations with disease-specific features, physical disability, and Quality of Life (QoL).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!